Radiosurgery Dose Reduction for Brain Metastases on Immunotherapy (RADREMI): A Prospective Pilot Study
The purpose of this study is to assess the efficacy and safety of a lower dose than is usually given of stereotactic radiosurgery (i.e. Gamma Knife or Linear Accelerator) for brain metastases patients receiving immunotherapy.
Researchers will collect a blood sample and information from participants' medical record. Participants will receive stereotactic radiosurgery (SRS) to a dose according to the size of their metastatic brain disease. Participants will undergo normal clinical (examinations) and radiographic (brain MRI with contrast) follow-up one month after SRS and every three months after SRS for a full year.
None of the procedures participants undergo will be experimental; all are standard of care. However, the lower dose of stereotactic radiosurgery they will receive is not standard of care.
- IRB Number: 1906336263
- Research Study Identifier: 1906336263
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required